08:41 AM EDT, 09/27/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that an investigational phase 1 study evaluating the combination of Talvey with Darzalex Faspro and pomalidomide in patients with relapsed or refractory multiple myeloma showed an overall response rate of 82%.

The company said the data supports continued investigation of the drug combination.

The study included patients who received at least three other therapies.

Multiple myeloma is a blood cancer affecting a type of white blood cell found in bone marrow.

Price: 161.57, Change: +0.18, Percent Change: +0.11